| 4.375 -0.015 (-0.34%) | 04-13 15:19 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 7.74 | 1-year : | 9.58 |
| Resists | First : | 6.63 | Second : | 8.21 |
| Pivot price | 4.4 |
|||
| Supports | First : | 4.07 | Second : | 3.39 |
| MAs | MA(5) : | 4.3 |
MA(20) : | 4.59 |
| MA(100) : | 4.69  |
MA(250) : | 3.3 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 28.8 |
D(3) : | 21.2 |
| RSI | RSI(14): 44.5 |
|||
| 52-week | High : | 8.21 | Low : | 0.53 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ CTMX ] has closed above bottom band by 38.0%. Bollinger Bands are 55.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 3 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 4.47 - 4.5 | 4.5 - 4.53 |
| Low: | 4.14 - 4.18 | 4.18 - 4.21 |
| Close: | 4.33 - 4.39 | 4.39 - 4.44 |
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical trials for the treatment of breast cancer; CX-2029 that is in Phase II clinical trials for the treatment of squamous non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal and gastro-esophageal junction cancers, and diffuse large B-cell lymphoma; BMS-986249, a CTLA-4 Probody therapeutic drug, which is in Phase I/II clinical trials for the treatment of metastatic melanoma; and BMS-986288, an anti-CTLA-4 Probody drug, which is in Phase I clinical trials for the treatment of solid tumors. It also develops CX-2043, a conditionally activated ADC targeting the epithelial cell adhesion molecule, as well as CX-904, a conditionally activated epidermal growth factor receptor for the treatment of solid tumor. The company has strategic collaborations with AbbVie Ireland Unlimited Company, Amgen, Inc., Bristol-Myers Squibb Company, ImmunoGen, Inc., Pfizer Inc., and Astellas Pharma Inc. to develop Probody therapeutics. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.
Sun, 12 Apr 2026
CytomX Therapeutics (CTMX) gains analyst confidence on trial progress - MSN
Sun, 12 Apr 2026
CytomX Therapeutics (CTMX) making progress on key metastatic colorectal cancer treatment - MSN
Sun, 12 Apr 2026
Analysts Bullish on CytomX Therapeutics (CTMX) As CTMX Prices $250 Million Offering - Yahoo Finance
Fri, 10 Apr 2026
How The CytomX Therapeutics (CTMX) Story Is Shifting With New Colorectal Cancer Data - Yahoo Finance
Fri, 20 Mar 2026
Jefferies Raises CytomX Therapeutics (CTMX) Price Target to $16 - Yahoo Finance
Mon, 16 Mar 2026
CytomX Therapeutics (CTMX) Reports Q4 Loss, Misses Revenue Estimates - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 216 (M) |
| Held by Insiders | 1.4816e+008 (%) |
| Held by Institutions | 0.6 (%) |
| Shares Short | 16,960 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.819e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | -22.8 % |
| Operating Margin | -3 % |
| Return on Assets (ttm) | 790.6 % |
| Return on Equity (ttm) | -9 % |
| Qtrly Rev. Growth | 7.62e+007 % |
| Gross Profit (p.s.) | -39.64 |
| Sales Per Share | -14.22 |
| EBITDA (p.s.) | 3.07258e+007 |
| Qtrly Earnings Growth | -0.2 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -76 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.31 |
| Price to Cash Flow | 18.53 |
| Dividend | 0 |
| Forward Dividend | 2.042e+007 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|